Vicenne’s Board of Directors, chaired by Adil Bennani, approved the company’s first-half financial statements on September 26, 2025, confirming the group’s strong upward trajectory. The figures reveal a sharp increase in revenue and profitability, driven by solid growth across all business lines.
Total revenue reached 527 million dirhams for the first six months of the year, representing a 44% jump from the 366 million recorded during the same period in 2024. This impressive growth reflects consistent performance across the company’s core segments. Equipment sales rose 43%, climbing from 216 million to 308 million dirhams. The implantables and reagents segment delivered an even more striking result, surging 54% to 164 million dirhams, up from 107 million a year earlier. Services also continued their upward trend, increasing 32% to reach 50 million dirhams compared to 38 million last year.
Gross margin rose sharply, up 50% to 197 million dirhams from 131 million, while the margin rate remained above 35%, underscoring the strength and resilience of Vicenne’s product and service portfolio. EBITDA came in at 126 million dirhams, a 64% increase from the previous year’s 77 million, highlighting both cost control and enhanced profitability. Net income attributable to the group soared to 83 million dirhams, a substantial 79% rise compared to the 46 million posted in the first half of 2024.
For the time being, Vicenne has opted not to include its Ivorian subsidiary Ivocare in the consolidated accounts, as the unit is still in its early development phase. The integration of Ivocare is planned for the full-year financial statements. The current consolidation perimeter includes Best Health Africa, Scrim, Soma Medical, Mabiotech, Chimiotech, MTS, and Saiss Environnement—all fully consolidated.
The company has reaffirmed its full-year targets, projecting consolidated revenue to exceed one billion dirhams and aiming for an EBITDA margin above 21%. This outlook is supported by the broader growth of Morocco’s healthcare sector, which continues to benefit from the ambitious reform program launched in 2022.
